KR20090126785A - Antioxidant composition containing pycnogenol, resveratrol and vitamines - Google Patents
Antioxidant composition containing pycnogenol, resveratrol and vitamines Download PDFInfo
- Publication number
- KR20090126785A KR20090126785A KR1020080053078A KR20080053078A KR20090126785A KR 20090126785 A KR20090126785 A KR 20090126785A KR 1020080053078 A KR1020080053078 A KR 1020080053078A KR 20080053078 A KR20080053078 A KR 20080053078A KR 20090126785 A KR20090126785 A KR 20090126785A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- resveratrol
- vitamin
- composition
- pycnogenol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 36
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 34
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 30
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 30
- 229920002770 condensed tannin Polymers 0.000 title claims abstract description 23
- 235000018192 pine bark supplement Nutrition 0.000 title claims abstract description 20
- 229940106796 pycnogenol Drugs 0.000 title claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 title claims description 31
- 235000006708 antioxidants Nutrition 0.000 title claims description 29
- 235000013343 vitamin Nutrition 0.000 title description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 22
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 13
- 229940046009 vitamin E Drugs 0.000 claims abstract description 13
- 239000011709 vitamin E Substances 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 11
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000304 folic acid Drugs 0.000 claims abstract description 11
- 235000019152 folic acid Nutrition 0.000 claims abstract description 11
- 239000011724 folic acid Substances 0.000 claims abstract description 11
- 235000011649 selenium Nutrition 0.000 claims abstract description 11
- 239000011669 selenium Substances 0.000 claims abstract description 11
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 11
- 235000013361 beverage Nutrition 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 5
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 5
- 239000008101 lactose Substances 0.000 claims abstract description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008117 stearic acid Substances 0.000 claims abstract description 5
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 239000002131 composite material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 206010012289 Dementia Diseases 0.000 abstract description 3
- 206010003246 arthritis Diseases 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 229940091258 selenium supplement Drugs 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 235000020095 red wine Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000219094 Vitaceae Species 0.000 description 5
- 235000021021 grapes Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000018991 trans-resveratrol Nutrition 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- -1 oxygen trioxide Chemical compound 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- IMOYOUMVYICGCA-UHFFFAOYSA-N 2-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C=C1C(C)(C)C IMOYOUMVYICGCA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241001593968 Vitis palmata Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 101000773110 Pelophylax lessonae Tyrosinase Proteins 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000005105 Pinus pinaster Nutrition 0.000 description 1
- 241001236212 Pinus pinaster Species 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002114 biscuit porcelain Inorganic materials 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 101150018117 cobB gene Proteins 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000013761 grape skin extract Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000008659 phytopathology Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 101150089009 sir2 gene Proteins 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 항산화 효과를 지니는 피크노제놀(pycnogenol), 레스베라트롤(resveratrol), 엽산(folic acid), 비타민C, 비타민E 및 셀레늄(selenium)을 포함하는 건강 기능성식품용 항산화 복합 조성물에 관한 것으로, 상세하게는 자유라디칼(free radical)을 소거하는 항산화 효과를 지니는 항산화 복합 조성물에 관한 것이다.The present invention relates to an antioxidant complex composition for health functional foods comprising an antioxidant effect of pycnogenol, resveratrol, folic acid, vitamin C, vitamin E and selenium. The present invention relates to an antioxidant complex composition having an antioxidant effect of eliminating free radicals.
인간을 포함한 모든 호기성 생물체는 산소를 이용한 에너지 대사 과정에서 항상 발생하는 활성산소의 상해에 대하여 근본적으로 자기방어 기구를 구비하고 있다. 그러나 예를 들어 인간의 경우 조직의 방어 능력을 초월한 활성산소의 생성은 최근 성인병이라 분류되는 관절염, 순환기장애 뿐만 아니라 노화촉진, 치매 등과 같은 여러 가지 질환의 원인이 되는 것으로 보고되었다(Halliwell et al., Drugs, 42, p569-605, 1991; Fukuzawa et al., J. Act. oxyg. Free Rad, 1, pp 55-70, 1990).All aerobic organisms, including humans, are essentially equipped with self-defense mechanisms against the injury of free radicals that always occur during the oxygen metabolism process. However, in humans, for example, the production of free radicals beyond the defenses of tissues has recently been reported to be a cause of various diseases such as arthritis and circulatory disorders as well as aging and dementia, which are classified as adult diseases (Halliwell et al. , Drugs, 42, p569-605, 1991; Fukuzawa et al., J. Act.oxyg.Free Rad, 1, pp 55-70, 1990).
흔히 유해산소라 불리는 활성산소는 가장 안정한 형태의 산소인 삼중화산 소(3O2)가 산화와 환원과정에서 환원되어 생성되는 일중항산소인 슈퍼옥사이드 음이온(Superoxide anion;1O2-), 과산화수소(H2O2) 또는 하이드록시라디칼(ㆍOH)과 같은 짝짓지 않은 상태의 자유 라디칼을 의미하고 그리고 이러한 자유 라디칼은 단백질, DNA, 효소 및 T세포와 같은 면역계통의 인자를 손상시켜 질환을 일으키는 것으로 알려져 있다(Regnstrom et al., Lancet, 16, pp 1183-1992; Gey et al., Am. Ac. J. Cin. Nutr, 53, pp 326, 1991).Active oxygen, commonly called noxious oxygen, is a single-oxygen superoxide anion ( 1 O 2- ), hydrogen peroxide, which is produced by the reduction of the most stable form of oxygen trioxide ( 3 O 2 ) during oxidation and reduction. Free radicals in an unpaired state, such as (H 2 O 2 ) or hydroxy radicals (.OH), and these free radicals damage diseases of the immune system such as proteins, DNA, enzymes and T cells (Regnstrom et al., Lancet, 16, pp 1183-1992; Gey et al., Am. Ac. J. Cin. Nutr, 53, pp 326, 1991).
이러한 이유로 항산화제에 대한 연구가 활발히 진행되어 효소계열인 예방적 항산화제인 슈퍼옥사이드 디스무테이제(Superoxide dismutase), 카탈레이즈(Catalase), 글루타치온퍼옥시데이즈(Glutathioneperoxidase) 등과 같은 항산화 효소와 천연항산화제인 비타민C, 비타민E, 카로티노이드(Carotenoid), 글루타치온(Glutathion) 및 합성 항산화제인 부틸히드록시아니졸(t-Butyl-4-hydroxyanisole; BHA), 디부틸히드록시톨루엔 (3,5-(t-Butyl)-4- hydroxytoluene; BHT)등 많은 항산화제가 개발되었다. 그러나 항산화 효소는 나이가 들어서 늙어감에 따라 활성산소에 대한 방어능력이 감소되고 그리고 합성 항산화제의 경우 그의 변이원성 및 독성이라는 약점을 가지므로 보다 안전하고 효력이 강한 천연 항산화제의 개발이 절실히 요청되고 있는 실정이다(Hatano et al., Natural Medicines, 49, pp359-363; Masaki et al., Biol. Pharm. Bull, 18, pp 162-166, 1995).For this reason, studies on antioxidants have been actively conducted, and antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase, which are enzyme-protective antioxidants, and vitamins, which are natural antioxidants, C, vitamin E, carotenoids, glutathione and synthetic antioxidants t-Butyl-4-hydroxyanisole (BHA), dibutylhydroxytoluene (3,5- (t-Butyl) Many antioxidants have been developed, including 4-hydroxytoluene (BHT). However, antioxidant enzymes have decreased defense against free radicals as they age, and synthetic antioxidants have their weak mutagenicity and toxicity.Therefore, there is an urgent need for the development of safer and more potent natural antioxidants. (Hatano et al., Natural Medicines, 49, pp 359-363; Masaki et al., Biol. Pharm. Bull, 18, pp 162-166, 1995).
피크노제놀은 프랑스 남서부에 있는 보르도지방에 서식하는 해송(Pinus maritima) 껍질에서 추출한 물질의 브랜드명이다. 보르도 대학 명예교수인 작 마스케리에 박사는 47년에 프랑스 해송껍질에서 폴리페놀의 일종인 OPC(Oligomeric Proantho Cyanidin)를 비롯하여 여러 종류의 기능성 성분을 발견, 추출하는데 성공했다. 피크노제놀의 주성분인 OPC는 소나무가 환경유독물질이나 기후상태에서 스스로를 지켜주는 항산화물질이다. 프랑스 해송은 비스케 해안의 모진 바람으로부터 스스로를 지키기 위해 강력한 항산화 물질을 만들어 내는 것이다. 피크노제놀은 우수한 항산화작용(미국특허 제4,698,360호)과 혈관보호작용(미국특허 제5,720,956호)이 있는 소재로 인정받아 현재 미국을 비롯한 여러 나라에서 건강식품으로 이용되고 있으며 프랑스에서는 이미 68년에 혈관보호약으로 승인을 받아 ‘플라반(Flavan)'이란 상품명으로 판매되고 있다.Pycnogenol is a brand name for a substance extracted from the bark of Pinus maritima in the Bordeaux region of southwest France. Dr. Jacques Maserie, an honorary professor at the University of Bordeaux, in 1984, discovered and extracted several functional ingredients, including OPC (Oligomeric Proantho Cyanidin), a polyphenol, in the sea shell of France. OPC, the main component of Pycnogenol, is an antioxidant that pines protect themselves from environmental pollutants and climatic conditions. The French seaweeds produce powerful antioxidants to protect themselves from the high winds on the Bisque coast. Pycnogenol is recognized as a material with excellent antioxidant activity (US Pat. No. 4,698,360) and vascular protection (US Pat. No. 5,720,956) and is currently used as a health food in many countries including the United States. The drug is approved under the name and sold under the trade name Flavan.
레스베라트롤(resveratrol)은 포도의 추출물로 레스베라트롤에 관한 연구는 1970년대부터 이루어져 왔고 특히 1992년에 Siemann과 Creasy에 의해 상업용 포도주에서 처음 레스베라트롤의 존재가 보고된 이래 매우 활발히 연구가 진행되고 있다. 레스베라트롤의 경우 인체에 미치는 독성이나 부작용, 특히 장기 복용의 경우 나타날 수 있는 약리 현상에 대하여 아직까지 연구된 바가 없다. 레스베라트롤은 탈아세틸 효소에 해당하는 sir2로 불리는 탈아세틸효소를 활성화시키며, 퀴논 환원효소(QR1)와 사이클로옥시게네이즈(COX)를 억제한다. Resveratrol is an extract of grapes, and research on resveratrol has been underway since the 1970s, especially since 1992 when Siemann and Creasy first reported the presence of resveratrol in commercial wines. Resveratrol has not been studied for toxic effects or side effects, especially pharmacological phenomena that can occur with long-term use. Resveratrol activates the deacetylase called sir2, which corresponds to the deacetylase, and inhibits quinone reductase (QR1) and cyclooxygenase (COX).
레스베라트롤은 나자식물 및 쌍자엽식물에 널리 분포되어 있으며 식물체 중에서 유리상태로 존재하기도 하나, 대부분 당류와 결합된 배당체의 형태로 존재한다 (Gorham, J., Prog. Phytochem., 6: 203-209, 1980). 그리고 레스베라트롤은 시 스형과 트랜스형이 있으며, 자연계에서는 몇몇을 제외하고는 대부분 안정한 트랜스 이성질체로 존재한다(Trela, B.C. ＆ Waterhouse, A.L., J. Agric. Food Chem., 44(5): 1253-1257, 1996).Resveratrol is widely distributed in the herbaceous and dicotyledonous plants and exists in the free state among plants, but mostly in the form of glycosides associated with sugars (Gorham, J., Prog. Phytochem., 6: 203-209, 1980 ). In addition, resveratrol is available in both cis and trans forms, and in nature, most of them exist as stable trans isomers (Trela, BC & Waterhouse, AL, J. Agric.Food Chem., 44 (5): 1253-1257 , 1996).
트랜스-레스베라트롤은 항암(Jang M., et al., Sci., 275: 218-220, 1997) 뿐만 아니라 항혈전(Chung, M.L. et al., Planta Med., 58: 274-276, 1992; Frankel, E.N. et al., Lancet, 341: 1103-1104, 1993; Bertrlli, A.A.E. et al., Int. J. Tissue React., 17: 1-3, 1995; Pae-Asciak, C.R. et al., Clin. Chim. Acta., 235: 207-219, 1995), 항염증(Kimura, Y. et al., Biochim. Biophys. Acta., 834: 275-278, 1985) 및 고지혈증(Arichi, H., et al, Chem. Pharm. Bull., 30(5): 1766-1770, 1982) 예방 효과가 있는 생리활성물질로서 잘 알려져 있다. 특히 최근 트랜스-레스베라트롤은 여성호르몬 에스트로겐 유사작용이 밝혀지면서 피토에스트로겐 (phytoestrogen)으로서 각광을 받고 있다(Gehm, B.D. et al., Proc. Natl. Acad. Sci., 94: 14138-14143, 1997). 한편, 레스베라트롤 유도체는 피부 멜라닌(melanin) 색소의 합성을 촉진하는 티로시나제 효소의 강력한 저해제로서 피부 미백효과가 우수한 물질로 보고되어 있다(Iida, K. et al., Planta Med., 61: 425-428, 1995; Shimizu K. et al., Planta Med., 64: 408-412, 1998). 이러한 트랜스-레스베라트롤의 치료효과는 이를 함유한 식물체의 생리적ㆍ약리적 작용에서 찾아볼 수 있다. 지금까지 발견된 대표적인 트랜스-레스베라트롤 함유 생약 및 식품으로서는 호장근, 대황, 포도 및 땅콩 등이 잘 알려져 있다(Ingham, J.L., Phytochem., 15: 1791-1793, 1976; Kimura, Y. et al., Planta Med., 49: 51-54, 1983; Kashiwada, Y., et al., Chem. Pharm. Bull., 32(9): 3501-3517, 1984; Jayatilake, G.S., et al., J. Natural Products, 56(10): 1805-1810, 1993). 특히 포도에서 발견된 트랜스-레스베라트롤은 당도 높은 포도가 곰팡이와 같은 감염균으로부터 자신의 몸을 보호하기 위해 생산하는 방어물질, 즉 피토알렉신(phytoalexin) 물질로 잘 알려져 있으며(Langcake, P., Pryce, R.J., Physiol. Planta Pathol., 9: 77-86, 1976), 백포도 보다 적포도 껍질에 많이 함유되어 있기에 적포도주를 즐겨 마시는 사람은 심장병에 의한 사망률이 낮는 사실과 깊은 연관이 있는 것으로 밝혀지고 있다(Goldberg, D.M., et al., Am. J. Enol. Vitic., 46(2): 159-165, 1995; Jeandet, P., et al., J. Phytopathology 143: 135-139, 1995). Trans-Resveratrol is not only anticancer (Jang M., et al., Sci., 275: 218-220, 1997) but also antithrombotic (Chung, ML et al., Planta Med., 58: 274-276, 1992; Frankel , EN et al., Lancet, 341: 1103-1104, 1993; Bertrlli, AAE et al., Int. J. Tissue React., 17: 1-3, 1995; Pae-Asciak, CR et al., Clin. Chim. Acta., 235: 207-219, 1995), anti-inflammatory (Kimura, Y. et al., Biochim. Biophys. Acta., 834: 275-278, 1985) and hyperlipidemia (Arichi, H., et al. , Chem. Pharm. Bull., 30 (5): 1766-1770, 1982) are well known as bioactive substances with prophylactic effects. Recently, trans-resveratrol has been spotlighted as a phytoestrogen with the discovery of female hormone estrogen-like action (Gehm, B.D. et al., Proc. Natl. Acad. Sci., 94: 14138-14143, 1997). On the other hand, resveratrol derivatives have been reported to be a powerful inhibitor of the skin tyrosinase enzyme that promotes the synthesis of skin melanin pigment (Iida, K. et al., Planta Med., 61: 425-428). , 1995; Shimizu K. et al., Planta Med., 64: 408-412, 1998). The therapeutic effect of such trans-resveratrol can be found in the physiological and pharmacological effects of plants containing the same. Representative trans-resveratrol-containing herbal medicines and foods discovered to date are well known Kho-Geun-Geun, rhubarb, grape and peanut (Ingham, JL, Phytochem., 15: 1791-1793, 1976; Kimura, Y. et al., Planta Med., 49: 51-54, 1983; Kashiwada, Y., et al., Chem. Pharm. Bull., 32 (9): 3501-3517, 1984; Jayatilake, GS, et al., J. Natural Products, 56 (10): 1805-1810, 1993). In particular, trans-resveratrol found in grapes is well known as a defensive substance, phytoalexin, produced by sugar-rich grapes to protect the body from fungi such as fungi (Langcake, P., Pryce, RJ, Physiol.Planta Pathol., 9: 77-86, 1976), It is found that people who drink red wine are more likely to be associated with lower mortality due to heart disease because they are found in red grape peels than white grapes. Goldberg, DM, et al., Am. J. Enol. Vitic., 46 (2): 159-165, 1995; Jeandet, P., et al., J. Phytopathology 143: 135-139, 1995).
피크노제놀 또는 레스베라트롤은 각기 독립적으로 제조되어 항산화물 형태로 제조, 판매되고 있다. 피크노제놀 단독 또는 프랑스해안송껍질 추출물(피크노제놀)에 비타민 C, 비타민 E, 달맞이꽃종자유를 혼합한 원료는 기능성원료로 인정받았지만 피크노제놀과 레스베라트롤이 복합적으로 사용된 경우, 또는 다른 건강 보조물과 혼합된 경우의 효능에 대해서는 알려지지 않았다. 본 발명은 피크노제놀 및 레스베라트롤이 복합적으로 사용하여 이들의 약리 효과 및 효능을 향상시킨 항산화 조성물을 제공한다.Pycnogenol or resveratrol are each manufactured independently and sold in the form of antioxidants. Efficacy of Pycnogenol alone or French Coastal Peel Extract (Pinoxenol) in combination with Vitamin C, Vitamin E and Evening Primrose Oil is recognized as a functional ingredient, but when Pycnogenol and Resveratrol are used in combination, or when mixed with other health supplements Is unknown. The present invention provides antioxidant compositions in which pycnogenol and resveratrol are used in combination to improve their pharmacological effects and efficacy.
본 발명의 목적은 피크노제놀, 레스베라트롤, 비타민C, 비타민E, 엽산 및 셀레늄을 적정비율로 혼합한 조성물을 제공하여, 항산화 효과뿐만 아니라 다른 질환을 예방할 수 있는 항산화기능이 향상된 건강 기능성 식품용 항산화 복합조성물을 제공하는 것이다. It is an object of the present invention to provide a composition containing a mixture of pycnogenol, resveratrol, vitamin C, vitamin E, folic acid and selenium in an appropriate ratio, antioxidant complex composition for health functional food with improved antioxidant function to prevent other diseases as well as antioxidant effect To provide.
또한 본 발명의 목적은 항산화 효과를 가진 각 성분들을 복합하고, 첨가 가능한 다른 첨가제를 함께 혼합하여 항산화 효과를 갖는 항산화 복합조성물을 제공하는 것이다. It is also an object of the present invention to provide an antioxidant complex composition having an antioxidant effect by combining each component having an antioxidant effect and mixing other additives that can be added together.
상기 과제를 해결하기 위하여, 본 발명의 적절한 실시 형태에 따르면, 전체중량에 대하여 피크노제놀 5~50 중량%, 레스베라트롤 5~50 중량%, 비타민C 15~30 중량 %, 비타민E 25~30 중량%, 셀레늄 0.02~0.04 중량 % 및 엽산 0.1~0.15 중량%를 포함하는 항산화 복합 조성물을 제공한다. In order to solve the above problems, according to a preferred embodiment of the present invention, 5-50% by weight of pycnogenol, 5-50% by weight of resveratrol, 15-30% by weight of vitamin C, 25-30% by weight of vitamin E, Provided is an antioxidant complex composition comprising 0.02-0.04% by weight selenium and 0.1-0.15% by weight folic acid.
본 발명의 다른 적절한 실시 형태에 따르면, 상기 조성물은 전체중량에 대하여 스테아린산 1.5~2.0중량%, 유당 8~10중량% 및 미결정상셀룰로오스 4~6중량%를 더 포함하는 항산화 복합 조성물을 제공한다. According to another suitable embodiment of the present invention, the composition provides an antioxidant composite composition further comprising 1.5 to 2.0% by weight stearic acid, 8 to 10% by weight lactose and 4 to 6% by weight microcrystalline cellulose relative to the total weight.
본 발명의 또 다른 적절한 실시 형태에 따르면, 상기 조성물은 건강 음료 또는 음료 첨가제로 사용되는 것을 특징으로 하는 항산화 복합 조성물을 제공한다.According to another suitable embodiment of the present invention, the composition provides an antioxidant complex composition, characterized in that it is used as a health beverage or beverage additive.
본 발명의 항산화 복합 조성물은 항산화 효과가 입증되어 단일제의 형태로 사용되어지는 물질들을 복합하여 제조한 것으로서 더욱 강력한 항산화 효과를 갖게 된다. 단일제로서 항산화 효과를 지니는 물질인 피크노제놀, 레스베라트롤, 엽산, 비타민C, 비타민E 및 셀레늄은 적절한 비율로 복합되어 강력한 항산화 효과가 발생된다. 본 발명에 따른 복합조성물은 과다하게 생성되는 활성산소의 영향으로 야기되어 질 수 있는 노화촉진, 관절염, 순환기장애, 치매 등과 같은 여러 질환을 예방하여 인간의 삶의 질을 향상시킬 수 있다. Antioxidant complex composition of the present invention has been proved to have an antioxidant effect and is produced by combining the materials to be used in the form of a single agent has a more powerful antioxidant effect. Pycnogenol, resveratrol, folic acid, vitamin C, vitamin E and selenium, which have antioxidant effects as a single agent, are combined in an appropriate ratio to produce a strong antioxidant effect. Complex composition according to the present invention can improve the quality of life of humans by preventing various diseases such as aging, arthritis, circulatory disorders, dementia, etc., which can be caused by the effects of excessively produced free radicals.
본 발명의 항산화 조성물은 필수 성분으로서 피크노제놀 및 레스베라트롤을 필수성분으로 포함한다. 피크노제놀은 조성물 전체 중량에 대하여 5~50 중량%인 것이 바람직하고, 보다 바람직하게는 10~25 중량%이다. 레스베라트롤은 조성물 전체 중량에 대하여 5~50중량%인 것이 바람직하고, 보다 바람직하게는 7~20중량%이다. The antioxidant composition of the present invention contains pycnogenol and resveratrol as essential ingredients. Pycnogenol is preferably 5 to 50% by weight, more preferably 10 to 25% by weight based on the total weight of the composition. Resveratrol is preferably 5 to 50% by weight, more preferably 7 to 20% by weight based on the total weight of the composition.
본 발명에서는 추가로 항산화효과를 향상시키기 위하여 본 발명의 조성물은 비타민 C, 비타민 E, 셀레늄 및 엽산을 포함하다. 각 성분의 함량은 전체중량에 대하여 비타민C 15~30 중량%, 비타민E 25~30 중량%, 셀레늄 0.02~0.04 중량% 및 엽산 0.1~0.15 중량%인 것이 바람직하다. 상기 혼합비율은 약리 효과를 시험하여 적절한 혼합 비율을 결정하였다. In the present invention, in order to further enhance the antioxidant effect, the composition of the present invention includes vitamin C, vitamin E, selenium and folic acid. The content of each component is preferably 15 to 30% by weight of vitamin C, 25 to 30% by weight of vitamin E, 0.02 to 0.04% by weight of selenium, and 0.1 to 0.15% by weight of folic acid. The mixing ratio was tested for pharmacological effects to determine the appropriate mixing ratio.
본 발명의 레스베라트롤은 자연 원료로부터 얻을 수 있는데, 바람직하게는 적포도주 추출물, 적포도 추출물, 포도씨 추출물, 포도껍질 추출물 및 호장근에서 추출할 수 있다. 포도는 국내에서 가장 많이 재배되고 있는 캠벨얼리와 거봉을 사 용할 수 있는데, 레스베라트롤 각각 2~3 μg/g, 3.24 μg/g으로 포함되어 있다. 레스베라트롤의 농도는 레드와인의 경우 화이트와인보다 10배가량 높으며, 이는 레드와인의 경우, 씨와 껍질이 좀 더 오래 남아 발효되기 때문에 레스베라트롤이 더욱 많이 추출되었기 때문이다. 일반적인 750ml 레드와인에 있어서 레스베라트롤의 농도는 0.6-15mg/l이다. 레스베라트롤은 통상적으로 에탄올 추출 시 더 수율이 좋아 적포도주에서 추출하기도 한다.The resveratrol of the present invention can be obtained from natural raw materials, and preferably, red wine extract, red grape extract, grape seed extract, grape skin extract, and knotweed extract. Grapes can be used the most cultivated in Korea, Campbell Early and Geobong, resveratrol is included in 2-3 μg / g, 3.24 μg / g respectively. The concentration of resveratrol is about 10 times higher than that of white wine in red wine, because in the case of red wine, resveratrol has been extracted more because the seeds and skin remain longer. In a typical 750 ml red wine, the concentration of resveratrol is 0.6-15 mg / l. Resveratrol is usually better in ethanol extraction and sometimes extracted from red wine.
상기 원료로부터 레스베라트롤을 추출하는 방법으로는 용매에 의한 추출법이 적용될 수 있다. 용매로는 친수성 용매, 유기용매 또는 그 둘의 혼합 용매가 적용될 수 있다. 필수적인 것은 아니지만 에탄올과 같은 알콜이 용매에 포함될 수 있다.As a method of extracting resveratrol from the raw material, an extraction method using a solvent may be applied. As the solvent, a hydrophilic solvent, an organic solvent or a mixed solvent of the two may be applied. Although not essential, alcohols such as ethanol may be included in the solvent.
추가로 다른 항산화 비타민 및 활력을 증진 시킬 수 있는 미네랄을 포함할 수 있다. 예로서 비타민류, 무기질류, 감마리놀렌산, 레시틴, 베타카로틴, CoQ10, DHA, EPA등을 포함할 수 있다. 상기 첨가제들은 전체중량에 대하여 10~20중량%로 포함될 수 있다. It may also contain other antioxidant vitamins and minerals that can enhance vitality. Examples include vitamins, minerals, gamma linolenic acid, lecithin, beta carotene, CoQ10, DHA, EPA and the like. The additives may be included in 10 to 20% by weight based on the total weight.
본 발명의 조성물은 캡슐형태 또는 정제로 제조될 수 있다. 캡슐로 제조되는 경우, 본 발명의 조성물을 담는 캡슐은 하드젤라틴 캡슐과 소프트젤라틴 캡슐을 사용할 수 있다. 캡슐을 구성하는 물질은 식용으로 할 수 있는 젤라틴(gelatin), 하이드록시프로필 메틸셀룰로오스(hydroxypropyl methylcellulose)나 녹말 등이 바람직하며 빛에 의한 산화과정을 막기 위해 티타늄 다이옥사이드 (Titanium dioxide)와 같은 금속 안료를 첨가하여 차광이 되도록 한다.The compositions of the present invention can be prepared in capsule form or in tablets. When the capsule is prepared, the capsule containing the composition of the present invention may use hard gelatin capsules and soft gelatin capsules. The material constituting the capsule is preferably gelatin, hydroxypropyl methylcellulose, or starch, which is edible. A metal pigment such as titanium dioxide is used to prevent oxidation by light. To be shaded.
본 발명의 조성물은 하기 실시예와 같이 캡슐형태로 제조될 수 있는데, 제안된 섭취량은 하루당 1 내지 4개의 캡슐이다. The composition of the present invention may be prepared in the form of a capsule as in the following examples, and the suggested intake is 1 to 4 capsules per day.
본 발명의 다른 실시형태로서 본 발명의 조성물을 함유하는 건강음료로 제조할 수 있고, 우유 및 요구르트와 같은 낙농제품에 첨가할 수도 있다.As another embodiment of the present invention, it can be prepared as a health beverage containing the composition of the present invention, and can be added to dairy products such as milk and yogurt.
이하 본 발명은 실시예 및 실험예를 통하여 상세하게 설명이 되지만, 제시된 실시예들이 본 발명의 범위를 제한하기 위한 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples, but the examples presented are not intended to limit the scope of the present invention.
실시예 1~3Examples 1-3
표 1에 나타낸 비율로 필수 성분에 해당하는 피크노제놀, 레스베라트롤, 비타민C, 비타민E, 엽산 및 셀레늄을 분말 상태로서 혼합한 후 혼합 믹서를 이용하여 10분간 잘 혼합하였다. 추가로 스테아르산 10mg, 유당 50mg 및 미결정상셀룰로오스 25mg을 더하여, 15분간 잘 혼합한 후, 수동캡슐 충진기 (KYP-100, KOREA MEDI)로 통상의 방법으로 캡슐을 제조하였다.Pycnogenol, resveratrol, vitamin C, vitamin E, folic acid and selenium, which are essential ingredients in the ratios shown in Table 1, were mixed as a powder and then mixed well for 10 minutes using a mixing mixer. In addition, 10 mg of stearic acid, 50 mg of lactose and 25 mg of microcrystalline cellulose were added and mixed well for 15 minutes, and then capsules were prepared by a conventional method using a manual capsule filling machine (KYP-100, KOREA MEDI).
비교예 1,2Comparative Examples 1,2
표 1에 나타낸 비율로 피크노제톨 또는 레스베라트롤을 엽산과 혼합한 다음, 상기 실시예와 동일한 방법으로 스테아린산, 유당, 미결정상실룰로오스를 혼합하여 캡슐을 제조하였다. Pycnogenol or resveratrol was mixed with folic acid at the ratios shown in Table 1, and then stearic acid, lactose and microcrystalline cellulose were mixed in the same manner as in the above example to prepare a capsule.
[표 1]TABLE 1
실시예 4Example 4
통상의 건강음료 제조방법에 따라 표 2의 성분비로 각 성분을 혼합한 다음, 약 1시간동안 15℃에서 교반한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료를 제조하였다.After mixing the ingredients in the component ratios of Table 2 according to the conventional healthy beverage production method, and stirred at 15 ℃ for about 1 hour, the resulting solution was filtered and obtained in a sterilized 2 L container, sealed sterilized and refrigerated Next, the health beverage of the present invention was prepared.
[표 2]TABLE 2
실험예 1Experimental Example 1
본 발명에서 실시예 1, 2 및 3의 복합 조성물의 항산화 효능을 확인하기 위하여, 자유 라디칼인 1,1-디페닐-2-피크릴히드라질(1,1-diphenyl-2-picrylhydrazyl, 이하 ‘DPPH’라 한다.)을 이용하여 실험하였다. In order to confirm the antioxidant efficacy of the composite compositions of Examples 1, 2 and 3 in the present invention, the free radical 1,1-diphenyl-2-picrylhydrazyl (1,1-diphenyl-2-picrylhydrazyl, hereinafter ' DPPH '.
DPPH는 2×10-4M 농도가 되도록 에탄올에 용해시켜 사용하였다. DPPH 1.5ml, 실시예 1, 2 또는 실시예 3의 복합제제(1000 ppm) 를 0.15ml, 증류수 1.35ml를 첨가하여 각각 30분, 60분, 15시간 실온에서 반응시킨 후, 520nm에서 흡광도를 측정하였다. DPPH 소거 효과는, 하기와 같은 수학식 1을 이용하여 계산된 DPPH 라디칼 소거활성 값이 50% 이상인 시료에 대하여 IC50 (50% inhibitory activity)을 비교하였다.DPPH was used by dissolving in ethanol to 2 × 10 -4 M concentration. 0.15 ml of DPPH 1.5 ml, Example 1, 2, or Example 3 complex preparation (1000 ppm) was added thereto, and 1.35 ml of distilled water were reacted at room temperature for 30 minutes, 60 minutes and 15 hours, respectively, and then the absorbance was measured at 520 nm. It was. For DPPH scavenging effect, IC 50 (50% inhibitory activity) was compared to a sample having a DPPH radical scavenging activity value of 50% or more calculated using Equation 1 below.
[수학식 1][Equation 1]
DPPH 라디칼 소거활성(%) = DPPH radical scavenging activity (%) =
((Acontrol-Bcontrol)-(Asample-Bsample))/(Acontrol-Bcontrol)×100((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도A control : Absorbance of control group without sample
Asample : 시료를 첨가한 반응군의 흡광도A sample : Absorbance of reaction group to which sample is added
Bcontrol : DPPH를 첨가하지 않은 대조군의 흡광도B control : Absorbance of control group without DPPH
Bsample : DPPH를 첨가하지 않은 반응군의 흡광도B sample : Absorbance of reaction group without DPPH
실시예 1~3, 비교예 1~2 성분의 각각 1000 ppm 농도에서 DPPH를 이용한 자유라디칼의 소거 효과를 측정하여 하기 표 3에 나타내었다.Examples 1 to 3, Comparative Examples 1 to 2 of the components at 1000 ppm concentration of each of the free radicals using the scavenging effect was measured in Table 3 below.
[표 3] TABLE 3
실험예Experimental Example 2-지질 과산화 억제 효과 측정 2-lipid peroxidation inhibitory effect measurement
자유라디칼 소거능이 우수한 본 발명의 복합 조성물을 가지고, 다음과 같이 배양된 세포를 이용하여 자외선에 의해 발생된 자유 라디칼에 의한 세포내 지질 과산화 억제 작용을 시험하였다. 사용된 세포는 V79-4 (햄스터 유래 섬유아세포종)를 사용하였다. 배지는 DMEM에 10% 소혈청을 첨가하여 사용하였으며 37℃, 5% CO2 조건에서 배양하였다. With the composite composition of the present invention having excellent free radical scavenging ability, cells cultured as follows were tested for the inhibition of intracellular lipid peroxidation by free radicals generated by ultraviolet light. The cells used were V79-4 (hamster derived fibroblastoma). The medium was used by adding 10% bovine serum to DMEM and cultured at 37 ℃, 5% CO 2 conditions.
상기 세포를 60 mm 세포배양 접시에 2 x 105 cells/dish의 농도로 접종하여 3일간 배양한다. 배양시 실시예 또는 비교예, 아스코르빈산을 배양액에 첨가하여 배양한다. 3일 후 배지를 따라 버리고 PBS 용액으로 2번 씻어준 후 1ml의 PBS를 배 양용기에 첨가해 준 후 일정한 광량 (15 J/cm2)의 자외선 A(UVA)를 조사해 준다. 조사 직후 PBS 용액을 실시예, 비교예 또는 아스코르빈산을 포함하는 정상적인 배지로 바꾸어 준 후 24시간 동안 더 배양한다.The cells are inoculated at a concentration of 2 x 10 5 cells / dish in a 60 mm cell culture dish and incubated for 3 days. At the time of cultivation, an Example or a comparative example, ascorbic acid is added to the culture, and cultured. After 3 days, pour out the medium, wash twice with PBS solution, add 1 ml of PBS to the culture vessel, and irradiate UV A (UV A ) with a constant amount of light (15 J / cm 2 ). Immediately after irradiation, the PBS solution is changed to a normal medium containing an example, a comparative example, or ascorbic acid, and further incubated for 24 hours.
세포에 생성된 지질 과산화물의 정량은 TBA(Thiobarbituric acid)반응성을 이용하여 수행하였으며 실험방법은 다음과 같다(Kari. P et al., J. Invest. Dermatol. 96 : 255-259, 1991). 먼저, 셀 스크래퍼(Cell scraper)를 이용하여 세포를 접시에서 떼어낸다. 1 ml의 균질화(Homogenization) 완충액에 현탁시킨 후 유리 균질기(homogenizer)를 이용, 세포를 분쇄한다. 이 세포 분쇄액 0.5 ml에 30% 트리클로로아세트산(Trichloroacetic acid, TCA) 0.5 ml과 50 μl의 2% 디부틸하이드록시 톨루엔(butylated hydroxy toluene, BHT) 에탄올 용액을 가한다. 여기에 0.5 ml의 TBA 수용액 (375 mg/ml)을 가한 후 끓는 물에 중탕으로 15분간 끓인다. 이것을 냉각시킨 후 535 nm에서 흡광도를 측정한다. 결과는 자외선을 처리하지 않는 대조군의 흡광도를 기준으로 하여 표기하였으며, 하기 표 4에 나타내었다. Quantification of lipid peroxides produced in cells was performed using TBA (Thiobarbituric acid) reactivity, and the experimental method was as follows (Kari. P et al., J. Invest. Dermatol. 96: 255-259, 1991). First, cells are removed from a plate using a cell scraper. After suspension in 1 ml of Homogenization buffer, cells are crushed using a free homogenizer. To 0.5 ml of this cell ground solution, 0.5 ml of 30% Trichloroacetic acid (TCA) and 50 μl of 2% butylated hydroxy toluene (BHT) ethanol solution are added. 0.5 ml of a solution of TBA (375 mg / ml) was added thereto, followed by boiling in boiling water for 15 minutes. After cooling it, the absorbance is measured at 535 nm. The results were expressed based on the absorbance of the control group not treated with ultraviolet rays, and are shown in Table 4 below.
[표 4] TABLE 4
상기 표 4에서 알 수 있듯이, 본 발명의 항산화 복합 조성물은 자외선에 의한 세포막 지질 과산화를 매우 효과적으로 막아줄 수 있다. 이는 피크노제놀, 레스베라트롤, 비타민C, 비타민 E, 셀레늄의 복합 조성물이 자외선에 의한 자유 라디칼 생성 및 지질 과산화를 억제함으로써 향상된 항산화력을 나타냄을 의미한다.As can be seen in Table 4, the antioxidant complex composition of the present invention can effectively prevent cell membrane lipid peroxidation by ultraviolet light. This means that the complex composition of pycnogenol, resveratrol, vitamin C, vitamin E, and selenium exhibits enhanced antioxidant power by inhibiting free radical generation and lipid peroxidation by ultraviolet rays.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080053078A KR20090126785A (en) | 2008-06-05 | 2008-06-05 | Antioxidant composition containing pycnogenol, resveratrol and vitamines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080053078A KR20090126785A (en) | 2008-06-05 | 2008-06-05 | Antioxidant composition containing pycnogenol, resveratrol and vitamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090126785A true KR20090126785A (en) | 2009-12-09 |
Family
ID=41687846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080053078A KR20090126785A (en) | 2008-06-05 | 2008-06-05 | Antioxidant composition containing pycnogenol, resveratrol and vitamines |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20090126785A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101882736B1 (en) * | 2017-07-10 | 2018-07-27 | 김삼 | Composition for skin protection comprising melatonin, vitamin C and pycnogenol as effective ingredient |
| CN112804990A (en) * | 2018-12-28 | 2021-05-14 | 罗尔夫·兰伯特博士制药咨询有限公司 | Liposome eye drops and application thereof in treating xerophthalmia |
-
2008
- 2008-06-05 KR KR1020080053078A patent/KR20090126785A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101882736B1 (en) * | 2017-07-10 | 2018-07-27 | 김삼 | Composition for skin protection comprising melatonin, vitamin C and pycnogenol as effective ingredient |
| CN112804990A (en) * | 2018-12-28 | 2021-05-14 | 罗尔夫·兰伯特博士制药咨询有限公司 | Liposome eye drops and application thereof in treating xerophthalmia |
| CN112804990B (en) * | 2018-12-28 | 2024-05-24 | 罗尔夫·兰伯特博士制药咨询有限公司 | Liposome eye drops and application thereof in treating xerophthalmia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060292255A1 (en) | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | |
| RU2330678C2 (en) | Compositions and methods of breast cancer treatment with morinda citrifolia and methylsulphonylmethane | |
| Romanucci et al. | Bioactive compounds of Aristotelia chilensis Stuntz and their pharmacological effects | |
| Pérez et al. | Chemistry of natural antioxidants and studies performed with different plants collected in Mexico | |
| WO2007002666A2 (en) | Pharmaceutical and therapeutic compostions derived from garcinia mangostana l plant | |
| US20100004344A1 (en) | Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition | |
| KR101402550B1 (en) | Antioxidizing Functional Cosmetic Compositions for Containing Extracted/Fermented Dendropanax morbifera Products and Functional Cosmetics Produced Thereby | |
| CN112493480B (en) | Antioxidant composition and application thereof | |
| KR101558184B1 (en) | Anti-aging composition containing red-grape-leaf extract berrylike mixtures and selenium | |
| KR20090126785A (en) | Antioxidant composition containing pycnogenol, resveratrol and vitamines | |
| Omoregie et al. | In vitro antioxidant activity and the effect of methanolic extracts of some local plants on nutritionally stressed rats | |
| KR101855989B1 (en) | Method for producing buckwheat seed extract with increased effective component using water adding solubilizer as extraction solvent and buckwheat seed extract produced by the same | |
| KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
| KR20140113050A (en) | A composition containing onion skin hot water extracts as a active ingredient for the treatment of diabetes mellitus and blood vessel disease | |
| Marnewick | Antioxidant Properties of Rooibos (Aspalathus linearis)—In Vitro and in Vivo Evidence | |
| JP2009007268A (en) | Salacia-processed product having improved absorptivity of xanthone and method for producing the same | |
| Guzmán-Beltrán et al. | Neuroprotective effect and reactive oxygen species scavenging capacity of Mangosteen pericarp extract in cultured neurons. | |
| KR101672827B1 (en) | Pharmaceutical composition for anti-oxidative or anti-inflammatory comprising leaf extract of alaskan ginseng | |
| KR101441291B1 (en) | Cosmetic composition comprising extract of Baby brier and Lespedeza cuneata for whitening and antioxdiant | |
| KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
| Apostol et al. | Extraction of Active Compounds from Armoracia rusticana Using Maceration and Ultrasound Assisted Extraction | |
| JP2009013103A (en) | Mangosteen-processed material having improved xanthone absorption and method for producing the same | |
| KR20180119234A (en) | Antioxidant Composition Using an Extract of Spodiopogon sibiricus | |
| JP2007143518A (en) | Betalain-containing food and cosmetic | |
| JP4215252B2 (en) | Antioxidants, skin cosmetics and beauty foods and drinks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |